Aushon’s Multiplex Immunoassay Platform Used to Validate Panel of Prognostic and Predictive Protein Biomarkers in Recent Phase II and Phase III Studies

June 10, 2011

Billerica, MA (June 10, 2011) Data was presented at the recent American Society of Clinical Oncology's 2011 Genitourinary Cancers Symposium showing multiple protein biomarkers predictive of clinical benefit and prognostic of disease outcome in patients with advanced or metastatic renal cell cancer.  This Phase III trial validated plasma cytokine and angiogenic biomarkers using Aushon’s multiplex immunoassay platform.
Download the poster>
The University of Texas MD Anderson Cancer Center also reported results from a Phase II study earlier last year, which demonstrated excellent correlation between Aushon’s platform and the ELISA across multiple biomarkers.
Download the poster>

“Until now, the single-plex ELISA has been the 'gold standard' for protein biomarker analysis in late stage clinical trials due to its perceived reliability”, said Peter Honkanen, CEO of Aushon. “Data from these Phase II and Phase III studies demonstrate that Aushon’s multiplex technology can perform as well as the ELISA, while providing all the other benefits of a next-generation, multiplex platform including convenience, reduced sample consumption, higher throughput and lower cost performance. This clearly demonstrates that Aushon's technology has met the stringent expectations in a late stage clinical trial setting where the performance bar is very high.”

About Aushon BioSystems

Aushon BioSystems provides a comprehensive suite of multiplex immunoassay products and services for protein biomarker discovery, development and analysis to leading pharmaceutical, biotechnology, academic and diagnostic clients worldwide. Our unique combination of advanced microarray printing technology, robust biomarker content and an innovative multiplex immunoassay technology platform delivers exceptional performance, quality and reliability that accelerate pre-clinical and clinical biomarker research. Our customers trust us to provide the most reliable protein biomarker data available, which lowers costs and improves research productivity. For more information, please visit  


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.